Test Background Vedolizumab (Entyvio©) is a humanised IgG1 antibody which inhibits the action of the mucosal trafficking α4β7 integrin and prevents migration of inflammatory T cells to the gut. Vedolizumab levels are measured in serum taken from patients just before an infusion (trough) using an indirect ELISA coated with α4β7 integrin
Clinical Indications For the monitoring of drug trough levels in IBD patients treated with Vedolizumab
Reference Range Results are reported between 0.8µg/ml and 96.0µg/ml. In the induction phase of the Entyvio© clinical trials week 6 trough levels were higher in responders than non-responders and higher trough levels were associated with increased mucosal healing in UC patients.
Sample Required Serum
Sample Container Rust Top Vacutainer
Sample Collection Samples should be taken just before the next infusion of drug (trough)
Sample Volume 0.5ml
ransport/Storage Transportation at room temperature/ first class post is adequate. Storage at 4 degrees or -20 for long term.
Turnaround Time 4 weeks
Notes Currently awaiting accreditation for this test